Haemonetics Corporation (HAE) has a consensus analyst rating of Buy, based on 20 analysts covering the stock. Of those, 10 recommend buying, 10 recommend holding, and 0 recommend selling.
The analyst consensus price target for HAE is $86.60, representing a +43.2% upside from the current price of $60.48. Price targets range from a low of $80.00 to a high of $94.00.
